尊龙凯时·(中国区)人生就是搏!

Genor Biopharma (Stock code: 6998.HK) announced that the research data of Lerociclib (GB491, a highly selective oral CDK4/6 inhibitor) Phase III clinical trial has been published in , titled as “Lerociclib plus Fulvestrant in Patients with HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy: LEONARDA-1 A Phase III Randomized Trial”, on January 16, 2025.

The 2024 Annual Meeting of the European Society of Medical Oncology (ESMO) has be held in Barcelona, Spain, from 13 to 17 September. As one of the largest, most academic and authoritative clinical oncology conferences in the world, the latest results of many important studies will be presented at the conference. Among them, the latest clinical trial data of GB263T GB263T (EGFR/cMET/cMET, TsAb) under Genor Biopharma (Stock code: 6998.HK) was released in the form of a poster on September 14.

Shanghai, China, August 28, 2024 – Genor Biopharma (Stock code: 6998.HK) today announced its interim results for 2024, sharing the company's business progress, financial data, highlights during the period, and future development prospects.

Shanghai, China, August 5, 2024 - Genor Biopharma (Stock code: 6998.HK) announced today that the company had entered into a licensing agreement and a stock purchase agreement with TRC 2004.Under the License Agreement, Genor Biopharma has agreed, among others, to grant the Licensee an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261 (CD20/CD3, BsAb) , excluding mainland China, Hong Kong, Macau and Taiwan.

Shanghai, China, March 28, 2024 – Genor Biopharma (Stock code: 6998.HK) announced today its 2023 annual financial results, business progress and other highlights in the past year.